El interés en corto de Quhuo da a los inversores una idea del grado en que los inversores apuestan por la caída de las acciones de Quhuo. Los datos de interés en corto se actualizan cada dos semanas.

Quhuo (NASDAQ:QH) Bolsa, Informe de interés en corto

Quhuo

Quhuo Ltd is a gig economy platform in China. The company provides tech-enabled, end-to-end operational solutions to consumer service businesses in industries with e-commerce exposure, including food delivery, ride-hailing, housekeeping, bike-sharing, and other services. The company generates revenue predominantly from service fees paid by its industry customers, and to a lesser extent, from rental fees under its car leasing agreements with drivers engaged in the ride-hailing solutions. It derives all of its revenue from the PRC. The company's revenues are categorized into On-demand delivery solutions; Mobility service solutions; Housekeeping solutions and other services. The On-demand delivery solutions generate key revenue for the firm.

Quhuo Limited - American Depository Shares

Quhuo Ltd

Innovator Hedged Nasdaq-100 ETF

QinHong International Group

WisdomTree U.S. High Yield Corporate Bond Fund

QHY Group

Scorpius Holdings (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/SCPX#AMEX">SCPX</a>) reported quarterly losses of $(1.43) per share. This is a 98.58 percent increase over losses of $(100.82) per share from the same period last year. The company reported $922.37 thousand in sales this quarter. This is a 27.55 percent increase over sales of $723.13 thousand the same period last year.

Earnings

News

SCPX

Scorpius Holdings Q3 EPS $(1.43) Up From $(100.82) YoY, Sales $922.37K Up From $723.13K YoY

Fusion Fuel Green Plc ("Fusion Fuel" or the "Company") announced today that it has issued a damages claim against Hydrogenial S.A. ("Hydrogenial" or the "Investor") and its principal, Mr. Norbert Bindner, following their failure to fund the $33.5 million Subscription Agreement disclosed in the Company's Form 6-K on September 11, 2024. Under the terms of this agreement, entered into in good faith by the Company on August 28, 2024, the Investor committed to purchase an aggregate of 43,790,850 Class A ordinary shares (the "Class A Shares"), along with warrants to acquire an additional 13,137,254 Class A Shares, for a total purchase price of $33,500,000.
Pursuant to Section 3 of the Subscription Agreement, the closing was to take place on September 30, 2024, with full payment due at or before the time of the closing. Despite all conditions to closing being met, as confirmed in discussions with Hydrogenial representatives, the Investor failed to fund in a timely fashion. The Company promptly informed Hydrogenial of its breach and requested immediate resolution, and Hydrogenial subsequently provided the Company with a revised closing date of October 25, 2024; however, to date, the Company has yet to receive proceeds from the investment. This continued delay has led Fusion Fuel to pursue legal recourse.
As a direct consequence of the funding delay, Fusion Fuel has filed for insolvency for its Portuguese subsidiary, Fusion Fuel Portugal S.A., out of which the most significant portion of the Company's technology sales and project development activities had been conducted. On the advice of insolvency counsel, the Company has submitted a claim in Portugal for damages incurred due to Hydrogenial's breach. The Company notes that the Investor's obligation under the Subscription Agreement remains in effect notwithstanding the filing of the claim and the insolvency of its Portuguese subsidiary.
In response to these events, Fusion Fuel is actively exploring strategic alternatives to preserve shareholder value, including a potential transaction that management believes could complement the Company's hydrogen business and yield significant synergies. The Company expects to provide further updates in short order.

HTOO

Fusion Fuel Issues Damages Claim Against Hydrogenial S.A. For Failure To Fund $33.5M Subscription Agreement; Announces Insolvency Of Portuguese Subsidiary, Fusion Fuel Portugal S.A.; Fusion Fuel Is Actively Exploring Strategic Alternatives To Preserve Shareholder Value, Including A Potential Transaction That Management Believes Could Complement The Company's Hydrogen Business And Yield Significant Synergies

MNOV

MediciNova Receives Notice Of Allowance From US PTO For A Pending Patent Application For MN-001 (Tipelukast) To Cover 'Method To Decrease Triglyceride Synthesis In A Liver Of A Subject'

Swedish video game company Embracer Group AB's (OTC:<a class="ticker" href="https://www.benzinga.com/stock/THQQF#OTC">THQQF</a>) latest financial results show a steep drop in sales and increased net losses as the company deals with game delays, staff <a href="https://www.benzinga.com/general/gaming">reductions, and restructuring.</a>
<h3 class="wp-block-heading">Q2 Financial Summary: Declining Sales And Higher Losses</h3>
For the quarter ending Sept. 30, Embracer reported (<a href="https://www.gamesindustry.biz/embracer-pc-and-console-sales-plummet-during-q2">via</a> GamesIndustry.biz) net sales of 8.55 billion SEK (about $774 million), down 21% from the same period last year.
See Also: <a href="https://www.benzinga.com/general/gaming/24/11/41985800/gta-5-joins-novembers-playstation-plus-lineup-with-other-fan-favorites">GTA 5 Joins November&#8217;s PlayStation Plus Lineup With Other Fan-Favorites</a>
Revenue from PC and console games took the largest hit, falling by 46% year-over-year to 2.12 billion SEK ($192 million), with only a few new releases and mixed reception of existing titles such as Disney Epic Mickey: Rebrushed. 
Mobile games saw an 8% decline, with revenue down to 1.35 billion SEK. The company recorded a net loss of 390 million SEK, a slight improvement from a 562 million SEK loss in the same quarter last year.
<h3 class="wp-block-heading">Six-Month Results: Losses And Reduced Workforce</h3>
Embracer's numbers for the first half of fiscal year 2025 reveal a sharper year-over-year decline. Net sales dropped 23% to 14.4 billion SEK, and its net loss widened to 2.58 billion SEK compared to a 1.69 billion SEK profit last year. 
Workforce reductions reflect the company's major restructuring efforts, with the number of game developers dropping from 10,654 to 6,250, and total headcount falling from 15,701 to 10,450.
<h3 class="wp-block-heading">Game Delays And Studio Divestments</h3>
A significant factor in Embracer's reduced revenues was a lack of major new releases and weaker-than-expected sales of its back catalog. 
Embracer also divested Gearbox and parts of Saber Interactive, affecting its revenue from older titles. CEO Lars Wingefors said, "Parts of our PC/Console and Entertainment &amp; Services segments are still underperforming due to delays and low ROI for primarily small and mid-sized releases." Embracer also recently sold Easybrain to Miniclip in a $1.2 billion deal as part of its efforts to reduce debt and streamline operations.
The company remains focused on core projects with a view toward longer-term growth, notably with the release of Kingdom Come: Deliverance 2, set to launch on Feb. 11, 2025, which Embracer expects will bring strong interest from the gaming community.
<h3 class="wp-block-heading">Outlook: Restructuring And Future Focus</h3>
Embracer anticipates continued lower earnings through the fiscal year, with Wingefors noting that the company has created "a stronger foundation for long-term value creation" by reducing debt and capital expenditures.
Embracer is also moving forward with plans to spin off Asmodee by the fiscal year-end, further refocusing its portfolio around core segments.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/gaming/24/11/41909832/call-of-duty-black-ops-6s-pacifist-player-reaches-prestige-without-any-kills">Call Of Duty: Black Ops 6&#8217;s Pacifist Player Reaches Prestige Without Any Kills</a></li>
</ul>
Image credits: Shutterstock.

Gaming

General

THQQF

Embracer's Earnings Struggle As Game Delays, Restructuring Weigh On Results

Fortress Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FBIO#NASDAQ">FBIO</a>) reported quarterly losses of $(0.76) per share which beat the analyst consensus estimate of $(1.15) by 33.91 percent. This is a 19.15 percent increase over losses of $(0.94) per share from the same period last year. The company reported quarterly sales of $14.63 million which missed the analyst consensus estimate of $32.22 million by 54.60 percent. This is a 57.90 percent decrease over sales of $34.75 million the same period last year.

Earnings Beats

Earnings Misses

FBIO

Fortress Biotech Q3 EPS $(0.76) Beats $(1.15) Estimate, Sales $14.63M Miss $32.22M Estimate

Operating expenses slashed by 22% year-over-year, falling to $3.9 million from $4.9 million in Q3 2023, reflecting efficiency gains.

WRAP

Wrap Technologies Reports Q3 Revenue Of $593K, Bringing 9-Month Revenue To $3.6M

BM Technologies (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/BMTX#AMEX">BMTX</a>) reported quarterly losses of $(0.42) per share which missed the analyst consensus estimate of $(0.20) by 110 percent. This is a 23.53 percent decrease over losses of $(0.34) per share from the same period last year. The company reported quarterly sales of $14.08 million which beat the analyst consensus estimate of $13.62 million by 3.36 percent. This is a 2.11 percent decrease over sales of $14.38 million the same period last year.

BMTX

BM Technologies Q3 Adj $(0.42) Misses $(0.20) Estimate, Sales $14.08M Beat $13.62M Estimate

<a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4303354-1&amp;h=1786564514&amp;u=http%3A%2F%2Fwww.standex.com%2F&amp;a=Standex+International+Corporation">Standex International Corporation</a>&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SXI#NYSE">SXI</a>) today announced that it has acquired Michigan-based Custom Biogenic Systems ("CBS") for approximately $6.2 million in cash. The transaction is being financed from Standex's existing cash balance. In its first year of ownership, the Company expects the acquisition to be accretive to its earnings. CBS will be reported as part of Standex's Scientific business segment.

Standex Acquires Custom Biogenic Systems For ~$6.2M In Cash

Greenland Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GTEC#NASDAQ">GTEC</a>) reported quarterly losses of $(0.05) per share which missed the analyst consensus estimate of $0.01 by 600 percent. This is a 28.57 percent increase over losses of $(0.07) per share from the same period last year. The company reported quarterly sales of $18.83 million which missed the analyst consensus estimate of $24.00 million by 21.53 percent. This is a 13.75 percent decrease over sales of $21.84 million the same period last year.

GTEC

Greenland Technologies Q3 EPS $(0.05) Misses $0.01 Estimate, Sales $18.83M Miss $24.00M Estimate

Trian Fund Management, the hedge fund led by Nelson Peltz, disclosed substantial portfolio changes in its third-quarter 13F filing, making notable exits from major companies before the <a href="https://www.benzinga.com/economics/macro-economic-events/24/11/41772701/trumps-historic-return-7-ways-his-second-term-could-impact-the-us-economy">2024 U.S. presidential election</a>. 
What Happened: The fund sold off its entire stakes in GE HealthCare Technologies Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GEHC#NASDAQ">GEHC</a>) (1.34 million shares), Walt Disney Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIS#NYSE">DIS</a>) (2.65 million shares) and Rentokil Initial plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RTO#NYSE">RTO</a>) (470,000 shares). 
These exits suggest a cautious pivot from sectors like healthcare and entertainment, which face both market challenges and macroeconomic pressures.
Trian also reduced its stakes in several core holdings. The fund cut its position in Wendy&#8217;s Co (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WEN#NASDAQ">WEN</a>) by 3%, reducing its shares from 31.5 million to 30.5 million, and scaled down its investment in asset manager Invesco Ltd (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IVZ#NYSE">IVZ</a>) by 15%, from 27.2 million to 23.1 million shares.
Read Also: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41988194/trump-plans-to-erase-ev-tax-credit-analyst-says-its-net-bullish-calls-sell-off-wrong-knee-jerk-reaction">Trump Plans To Erase EV Tax Credit: Tesla Analyst Says It&#8217;s &#8216;Net Bullish,&#8217; Calls Sell-Off &#8216;Wrong Knee-Jerk Reaction&#8217;</a>
The most substantial reduction came in Allstate Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALL#NYSE">ALL</a>), where Trian slashed its holdings by 69%, to 613,447 shares. These reductions reflect a strategic tightening in sectors affected by recent market volatility and economic uncertainty.
What Else: However, Trian strengthened its position in select companies, raising its stake in Solventum Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SOLV#NYSE">SOLV</a>) from 5.36 million to 7.13 million shares, and held its positions steady in Janus Henderson Group PLC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JHG#NYSE">JHG</a>) and General Electric Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GE#NYSE">GE</a>) as its top holdings.
This targeted increase aligns with Trian's confidence in sectors that may benefit from potential industrial and financial sector growth.
Soon after Trian's portfolio moves in the third quarter, Donald Trump's victory in the 2024 U.S. presidential election was confirmed, along with a Republican majority in the Senate.
Trump's policy agenda, which includes corporate tax cuts, increased tariffs and a potential rollback of green energy initiatives, is expected to significantly impact markets. 
Sectors like traditional manufacturing, defense and energy may see gains under Trump's administration, aligning with Trian's portfolio shifts, especially in industrial and financial investments.
Trian's recent moves highlight a forward-looking strategy as the hedge fund prepares for an evolving economic landscape shaped by Trump's return to the White House.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/11/41984278/jim-simons-renaissance-technologies-shifts-gears-microsoft-in-tesla-out-palantir-on-top">Jim Simons&#8217; Renaissance Technologies Shifts Gears: Microsoft In, Tesla Out, Palantir On Top</a></li>
</ul>
Image created using artificial intelligence via Midjourney.

Hedge Funds

Politics

GEHC

Janus Henderson Group plc Ordinary Shares

SOLV

Nelson Peltz's Trian Fund Management Reshaped Portfolio Ahead Of Presidential Election

DHAI

DIH Holding US Q2 EPS $(0.01) Up From $(0.10) YoY, Sales $18.2M Up From $13.1M YoY

Fundamental Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FGF#NASDAQ">FGF</a>) reported quarterly earnings of $15.06 per share. This is a 288.01 percent increase over losses of $(8.01) per share from the same period last year. The company reported $10.45 million in sales this quarter. This is a 155.82 percent increase over sales of $4.09 million the same period last year.

Fundamental Global Q3 EPS $15.06 Up From $(8.01) YoY, Sales $10.45M Up From $4.09M YoY

flyExclusive (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/FLYX#AMEX">FLYX</a>) reported quarterly losses of $(0.32) per share. The company reported $76.92 million in sales this quarter. This is a 24.02 percent increase over sales of $62.03 million the same period last year.

FLYX

flyExclusive Q3 EPS $(0.32), Sales $76.92M Up From $62.03M YoY

Chardan Capital analyst Geulah Livshits maintains Passage Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PASG#NASDAQ">PASG</a>) with a Buy and maintains $7 price target.

Price Target

Analyst Ratings

PASG

Chardan Capital Maintains Buy on Passage Bio, Maintains $7 Price Target

—Becomes first company to showcase four routes of synthesis for approved siRNA therapeutic asset—
—Joint poster with Bachem demonstrates superiority of Company's double-stranded RNA ligases compared to wild-type enzymes—
—Management to host conference call today at 4:30 pm EST to discuss data—
REDWOOD CITY, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDXS#NASDAQ">CDXS</a>), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced data from three presentations at the TIDES Europe annual meeting being held November 12-14, 2024, in Hamburg, Germany. The data demonstrate the Company's rapid advancement of its Enzyme Catalyzed Oligonucleotide (ECO) Synthesis&#x2122; manufacturing platform and establish Codexis' position at the forefront of enzymatic synthesis technology to enable to ongoing expansion of RNAi therapeutics.

Biotech

CDXS

Codexis Unveils Pioneering Enzymatic Synthesis Data To Enable The Future Manufacturing Of RNAi Therapeutics; Management Hosted Conference Call Today At 4:30 pm EST To Discuss Data

Phio Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PHIO#NASDAQ">PHIO</a>) reported quarterly losses of $(1.54) per share which beat the analyst consensus estimate of $(4.14) by 62.8 percent.

PHIO

Phio Pharma Q3 2024 GAAP EPS $(1.54) May Not Be Comparable To $(4.14) Estimate

Thunder Power Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIEV#NASDAQ">AIEV</a>) reported quarterly losses of $(0.02) per share. This is unchanged from the same period last year.

AIEV

Thunder Power Holdings Q3 EPS $(0.02), Same YoY

Avenue Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATXI#NASDAQ">ATXI</a>) reported quarterly losses of $(1.92) per share which missed the analyst consensus estimate of $(0.94) by 104.26 percent. This is a 139.51 percent decrease over earnings of $4.86 per share from the same period last year.

ATXI

Avenue Therapeutics Q3 EPS $(1.92) Misses $(0.94) Estimate

Legal

GREE

Greenidge Says New York Supreme Court Judge Rejected Department Of Environmental Conservation's Action To Deny Its Application For Renewal Of Title V Air Permit

Aqua Metals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AQMS#NASDAQ">AQMS</a>) reported quarterly losses of $(0.76) per share which beat the analyst consensus estimate of $(0.80) by 5 percent. This is a 14.61 percent increase over losses of $(0.89) per share from the same period last year.

AQMS

Aqua Metals Q3 EPS $(0.76) Beats $(0.80) Estimate

Quhuo (QH) has released an update. Quhuo Limited has completed the conversion of senior convertible promissory notes into 793,868,246 Class A ordin...

Quhuo Limited Converts Notes to Class A Shares

Quhuo reports 1H results

Quhuo (QH) has released an update. Quhuo Limited has released its unaudited interim condensed consolidated financial statements, revealing a decrea...

Quhuo Limited Reports Mid-Year Financials

Quhuo Limited (QH) Q2 2024 Earnings Conference Call Transcript

Quhuo Limited files to sell $79.39M ADS by holders

Quhuo Ltd., BIO-Key International, and iLearningEngines Holdings are the 3 Penny Stocks to watch on September 12, 2024, based on&nbsp;TipRanks' Pen...

3 Penny Stocks to Watch Now, 9/12/24

Quhuo (QH) has released an update. Quhuo Limited has secured a credit facility agreement with Xiamen Bank, allowing access to working capital loans...

Quhuo Limited Secures RMB 20 Million Credit Facility

Quhuo regains compliance with Nasdaq

Quhuo (QH) has released an update. Quhuo Limited, a leading gig economy platform in China, has successfully regained compliance with Nasdaq's listi...

Quhuo Limited Secures Nasdaq Listing Compliance

Quhuo (QH) announced a strategic partnership with Panasonic Navinfo, a joint venture company. The collaboration aims to strengthen export support f...

Comments

Quhuo

Interés en corto

Quhuo (NASDAQ:QH) Bolsa, Informe de interés en corto

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL